MDXH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

30.55M

+23.73%

-0.126

-10%

31.70M

+30.9%

-0.098

-48.68%

32.71M

+22.99%

-0.085

-39.29%

Estimates Revision

The market is revising Downward the revenue expectations for MDxHealth SA (MDXH) for FY2025, with the revenue forecasts being adjusted by -1.26% over the past three months. During the same period, the stock price has changed by -12.89%.

Revenue Estimates for FY2025

Revise Downward

-1.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+14.29%

In Past 3 Month

Stock Price

Go Down

-12.89%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast MDXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXH is 7.67 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.310

Low

7.00

Averages

7.67

High

9.00

Current: 3.310

Low

7.00

Averages

7.67

High

9.00

BTIG

Buy

maintain

$6 -> $7

2025-11-13

Reason

BTIG

Price Target

$6 -> $7

2025-11-13

maintain

Buy

Reason

BTIG raised the firm's price target on MDxHealth to $7 from $6 and keeps a Buy rating on the shares. The company drove a big uplift in its liquid-based test volumes in Q3 in part due to strength from its Resolve test and new contribution from its recently acquired ExoDx test, which the company recently acquired from Bio-Techne, the analyst tells investors in a research note. MDxHealth's reported Q3 was also highlighted by robust volume growth, the firm added.

TD Cowen

Buy

upgrade

$5 -> $7

2025-11-13

Reason

TD Cowen

Price Target

$5 -> $7

2025-11-13

upgrade

Buy

Reason

TD Cowen raised the firm's price target on MDxHealth to $7 from $5 and keeps a Buy rating on the shares. The firm said 3Q sales were just shy of consensus with margins/EBITDA better. 2026 should see accelerating sales growth as ExoDx integration takes full effect, which combined with OpEx control will enable expanding positive EBITDA, supporting a favorable view on the shares.

Lake Street

Buy

upgrade

$7 -> $9

2025-11-13

Reason

Lake Street

Price Target

$7 -> $9

2025-11-13

upgrade

Buy

Reason

Lake Street raised the firm's price target on MDxHealth to $9 from $7 and keeps a Buy rating on the shares. Following the Q3 report, the firm is increasing its price target to reflect the improved profile of the company's portfolio and revenue growth prospects in 2026, the analyst tells investors.

Craig-Hallum

NULL -> Buy

initiated

2025-07-17

Reason

Craig-Hallum

Price Target

2025-07-17

initiated

NULL -> Buy

Reason

Craig-Hallum initiated coverage of MDxHealth with a Buy rating and $8 price target.

Craig-Hallum

William Bonello

initiated

2025-07-17

Reason

Craig-Hallum

William Bonello

Price Target

2025-07-17

initiated

Reason

As previously reported, Craig-Hallum analyst William Bonello initiated coverage of MDxHealth with a Buy rating and $8 price target. The firm notes MDxHealth has the only test to evaluate the risk of undetected cancer in men with a negative biopsy. It also has a test to determine whether men classified as having low-risk cancer actually have more aggressive cancer that needs to be treated. The first test has a $500M TAM that is less than 10% penetrated, and the second test has a $600M TAM that is just 40% penetrated. Craig-Hallum is looking for 20%-plus topline growth with EBITDA breakeven this quarter, with the potential for mid-teens margins in a couple of years. The company has beaten top-line estimates in each of the past nine quarters, and also trades at less than 2-times this year's revenue - which is a steep discount to the group.

Valuation Metrics

The current forward P/E ratio for MDxHealth SA (MDXH.O) is -8.84, compared to its 5-year average forward P/E of -4.48. For a more detailed relative valuation and DCF analysis to assess MDxHealth SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.48

Current PE

-8.84

Overvalued PE

-1.54

Undervalued PE

-7.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.47

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

40.89

Undervalued EV/EBITDA

-69.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.19

Current PS

0.00

Overvalued PS

2.13

Undervalued PS

0.25

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MDXH News & Events

Events Timeline

No data

News

6.0

11-13Benzinga

BTIG Reaffirms Buy Rating on MDxHealth, Increases Price Target to $7

8.5

09-21Yahoo Finance

MDxHealth Finalizes Acquisition of Bio Techne's ExoDx to Enhance Precision Diagnostics

7.0

01-13Business Insider

MDxHealth Q4 Preliminary Revenue Climbs; Initiates 2025 Revenue Outlook

People Also Watch

Frequently Asked Questions

What is MDxHealth SA (MDXH) stock price today?

The current price of MDXH is 3.31 USD — it has decreased -0.3 % in the last trading day.

What is MDxHealth SA (MDXH)'s business?

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

What is the price predicton of MDXH Stock?

What is MDxHealth SA (MDXH)'s revenue for the last quarter?

MDxHealth SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is MDxHealth SA (MDXH)'s earnings per share (EPS) for the last quarter?

MDxHealth SA. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for MDxHealth SA (MDXH)'s fundamentals?

How many employees does MDxHealth SA (MDXH). have?

MDxHealth SA (MDXH) has 312 emplpoyees as of December 16 2025.

What is MDxHealth SA (MDXH) market cap?

Today MDXH has the market capitalization of 163.84M USD.